What is DBV Technologies?
Founded in 2002, DBV Technologies is a bio-pharmaceutical company dedicated to the research and development of novel medical treatments and technologies. Operating as a B2B enterprise, its core focus lies in leveraging scientific innovation and rigorous clinical research to advance healthcare solutions. With established operations spanning Europe and North America, DBV Technologies plays a role in the global biopharmaceutical landscape, contributing specialized medical and health technologies.
How much funding has DBV Technologies raised?
DBV Technologies has raised a total of $808.3M across 9 funding rounds:
Series B
$6.6M
Series C
$25.5M
Stock Offering
$44.5M
Share Placement
$33.9M
Stock Offering
$153.7M
Share Placement
$194M
Other Financing Round
$306.9M
Stock/Share Issuance
$30M
Series B (2009): $6.6M led by Sofinnova Partners and ALK-Abello
Series C (2011): $25.5M supported by Shire Pharmaceuticals, InnoBio Fund, Alto Invest, Lundbeckfonden Ventures, Sofinnova Partners, and ALK Abello
Stock Issuance/Offering (2012): $44.5M, investors not publicly disclosed
Share Placement (2013): $33.9M backed by ALK Abello, Altamir, Innobio, Lundbeckfond, and Apax Partners
Stock Issuance/Offering (2020): $153.7M, investors not publicly disclosed
Share Placement (2022): $194M, investors not publicly disclosed
Other Financing Round (2025): $306.9M supported by Janus Henderson Investors, Yiheng Capital, Octagon Capital Group, Vivo Capital, MPM BioImpact, Bpifrance, Adage Capital Management, and Surveyor Capital
Stock/Share Issuance (2025): $30M, investors not publicly disclosed
Key Investors in DBV Technologies
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact the company's collective future.
Apax Partners
Apax Partners is a leading global private equity advisory firm that has raised approximately $80 billion in aggregate funds over more than four decades of operation. The firm is distinguished by its sector-led investment strategy, focusing exclusively on four key global industries: Tech, Services, and Internet/Consumer. Apax creates value by partnering with high-potential management teams and providing them with a specialized mix of operating skills and deep digital expertise, often referred to as their "Digital DNA" approach. The firm operates across several distinct strategies, including Apax Global Buyout, which focuses on upper mid-market control investments; Apax Digital Growth, which backs technology leaders and entrepreneurs; and Apax Global Impact, which targets companies delivering tangible societal or environmental outcomes. Supported by an in-house Operational Excellence Practice (OEP) of over 350 specialists, Apax helps its portfolio companies optimize critical initiatives and navigate complex market disruptions. As of 2026, the firm maintains a truly global footprint with offices in major financial hubs including Abu Dhabi, Hong Kong, Mumbai, Munich, Shanghai, and Tel Aviv, continuing to drive mutual success through long-term partnerships and a culture of collaborative ownership.
Vivo Capital
Vivo Capital founded in 1996 and headquartered in Palo Alto, California, is a global healthcare investment firm focused on private and public equity as well as venture capital.
What's next for DBV Technologies?
The recent major strategic investment signals a pivotal phase for DBV Technologies, likely aimed at accelerating its product development pipeline, expanding clinical trial reach, or scaling its commercialization efforts. Given the enterprise-level nature of its funding, the company is poised for significant growth and market penetration. Future strategic moves may involve further partnerships, regulatory approvals, and the broader adoption of its innovative medical technologies, solidifying its position in the competitive biopharmaceutical sector.
See full DBV Technologies company page
